AG真人官方

Insider Sale: Executive Vice President & Head of Institutional Bank John Leto filed a Form 4 for The Bancorp Inc. (TBBK).

• Transaction date: 08/01/2025
• Securities: 50,000 common shares sold (Code 鈥淪鈥�)
• Average price: $60.3482 (price range $60.00-$61.56)
• Post-sale holdings: 114,111 shares held directly; 3,540 shares held indirectly via 401(k)

No derivative trades were reported, and the filing was made by a single reporting person. Based on the stated amounts, the executive disposed of roughly 30% of his prior direct position (50,000 of ~164,111 shares), reducing鈥攜et still leaving鈥攁 sizeable equity stake.

The absence of earnings or corporate event disclosures means this filing is purely a record of insider activity; investors often view sizable insider sales as a potential negative sentiment signal, though motives can vary (liquidity, diversification, preset plans).

Form 4 snapshot: On 07/31/2025, Kyndryl Holdings (KD) director Janina Kugel received 6,296 restricted stock units (RSUs) of common stock at a reference price of $38.12. Following the award, her direct beneficial ownership increases to 48,310 shares.

The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the 2026 Annual Meeting of Stockholders, provided that meeting occurs at least 50 weeks after the 2025 meeting. No derivative securities were reported.

This appears to be a routine, board-level equity compensation grant, signalling continuing alignment between the director and shareholders rather than indicating any directional view on KD鈥檚 near-term share performance.

Form 144 filing: An insider has notified the SEC of an intent to sell 1,694 JFrog Ltd. (FROG) common shares through UBS Financial Services on or after 01 Aug 2025. The shares carry an estimated aggregate market value of $71,927 and represent only about 0.0015 % of the 114.57 million shares outstanding, making the transaction immaterial to the company鈥檚 capital structure.

The shares were acquired the same day via a cash-settled stock-option exercise. During the prior three months the same seller disposed of 32,891 shares for gross proceeds of roughly $1.39 million, suggesting continued but modest portfolio diversification.

The notice contains no operational or financial updates and is a routine Rule 144 compliance filing. Market impact should remain negligible unless the cadence or magnitude of future insider sales accelerates.

Silexion Therapeutics (SLXN) filed an 8-K announcing a warrant-inducement deal that delivers roughly $1.8 million in gross cash immediately. On 31 Jul 2025 certain holders agreed to exercise 152,106 pre-existing warrants at a reduced $11.57 strike (down from $20.25鈥�$22.50) following the company鈥檚 1-for-15 reverse split. In consideration, the company will issue 304,212 new two-year warrants priced at $11.32 plus 10,647 placement-agent warrants at $14.4625. All new warrants become exercisable once shareholders approve an authorized-capital increase at the 12 Aug 2025 EGM; each holder is limited to 4.99 % (optionally 9.99 %) beneficial ownership.

H.C. Wainwright & Co. will earn a 7 % placement fee, 1 % management fee and up to $90 k in expenses, and will receive the agent warrants. Net proceeds are earmarked for general corporate purposes. The company committed to file a resale S-3 within 30 days and to keep it effective until all new warrants are exercised, while refraining from additional equity issuance for 15 days and from variable-rate financings for one year.

The transaction boosts near-term liquidity but introduces significant potential dilution鈥攏ew and agent warrants represent more than double the shares issued now, and there is currently no trading market for the warrants.

Bank of Montreal (BMO) and its affiliates have become a 5%+ holder of Kochav Defense Acquisition Corp. (KCHVU). A Schedule 13G dated 30 Jun 2025 shows Bank of Montreal, Bank of Montreal Holding Inc. and BMO Nesbitt Burns Inc. beneficially own 2,150,000 units鈥攅ach unit equal to one Class A ordinary share and one right鈥攔epresenting 8.33 % of the outstanding class.

All voting and dispositive power is shared; the filers report 0 units with sole power. The stake is held in the ordinary course of business while acting as prime broker for certain clients, and the parties certify they are not seeking to influence control of the issuer. The filing is made under Rule 13d-1(b) with classifications HC (holding company), BK (bank) and BD (broker-dealer).

No financial metrics, strategic commentary or change-of-control intentions are provided. The disclosure simply alerts investors that a large, reputable Canadian financial institution now reports ownership above the 5 % threshold, a potential signal of institutional interest but with limited immediate impact on the SPAC鈥檚 fundamentals.

Schedule 13G/A (Amendment 2) filed 31 Jul 2025 shows that four Canadian investment advisers linked to Scotiabank 鈥� 1832 Asset Management L.P., MD Financial Management Inc., Scotia McLeod (Scotia Capital Inc.) and Jarislowsky, Fraser Ltd 鈥� collectively owned 22,630,889 Brookfield Infrastructure Partners (BIP) LP units on 30 Jun 2025, equal to 4.90 % of the outstanding class.

Voting/dispositive authority is largely unilateral: sole power over 22,603,439 units and shared power over only 27,450 units. Individual stakes are: 1832 AM 15.45 m units (3.35 %), Scotia McLeod 7.15 m (1.55 %), MD Financial 25 k (0.01 %) and Jarislowsky Fraser 3.2 k (<0.01 %).

The group now certifies ownership of 5 % or less, indicating a position below the threshold that would otherwise trigger Schedule 13D obligations. The securities are held in the ordinary course of business with no intent to influence control.

Amendment No. 2 to Schedule 13G shows that Foundations Investment Advisors, LLC, an Arizona-based registered investment adviser, held 32,442 units of Innovator Equity Managed Floor ETF (CUSIP 45783Y806) on 30 Jun 2025, equal to 10.0 % of the outstanding class. The firm reports sole dispositive power over the entire position but zero voting power, filing under Rule 13d-1(b) applicable to investment advisers.

No other parties form a group and no subsidiary executed the purchase. Standard certifications are included and the document is signed by CCO Marc Pugsley on 29 Jul 2025. The filing signals that an institutional investor now holds a sizable, passive stake, potentially improving perceived support and liquidity for the ETF while concentrating ownership in a single adviser.

Medpace Holdings, Inc. (MEDP) 鈥� Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller鈥檚 name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Enovix Corp (ENVX) 鈥� Form 4 insider filing

Chief Accounting Officer Kristina Truong reported a Code F transaction on 07/13/2025, indicating that 1,013 common shares were withheld to cover taxes upon the vesting of restricted stock units (RSUs). The shares were valued at $14.07 each, an implied tax-withholding value of roughly $14,200. Following the withholding, the insider鈥檚 direct beneficial ownership stands at 207,112 common shares, which includes 173,617 un-settled RSUs.

No open-market purchases or sales occurred, and no new derivative positions were created or exercised. The filing is largely administrative, reflecting routine equity compensation settlement rather than a discretionary trade.